Can we prevent or treat renal dysfunction in acute heart failure?

[1]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[2]  C. Ronco,et al.  The Cardiorenal Syndrome , 2011, International journal of nephrology.

[3]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[4]  G. Parati,et al.  Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure , 2011, Journal of cardiovascular medicine.

[5]  C. Ronco,et al.  Current and future role of ultrafiltration in CRS , 2011, Heart Failure Reviews.

[6]  Dirk Westermann,et al.  Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. , 2010, Journal of cardiac failure.

[7]  J. Butler,et al.  Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. , 2010, Circulation. Heart failure.

[8]  M. Nieminen,et al.  Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. , 2010, European heart journal.

[9]  G. Felker,et al.  Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. , 2010, International journal of cardiology.

[10]  P. Ponikowski,et al.  Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.

[11]  F. Aucella,et al.  How to assess renal function in the geriatric population. , 2010, Journal of nephrology.

[12]  P. Ponikowski,et al.  The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. , 2010, Journal of cardiac failure.

[13]  A. Kazory.  Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. , 2010, The American journal of cardiology.

[14]  M. Sarnak,et al.  Cardiovascular disease and CKD: core curriculum 2010. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  G. Navis,et al.  Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate , 2010, Heart.

[16]  S. Kimmel,et al.  Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and Survival , 2010, Circulation.

[17]  A. Burger,et al.  The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. , 2010, Journal of cardiac failure.

[18]  M. Gheorghiade,et al.  Congestion as a therapeutic target in acute heart failure syndromes. , 2010, Progress in cardiovascular diseases.

[19]  Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative , 2009, European heart journal.

[20]  P. Ponikowski,et al.  Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). , 2010, Contributions to nephrology.

[21]  Rinaldo Bellomo,et al.  Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  R. Shah,et al.  Managing acute renal failure in patients with acute decompensated heart failure: The cardiorenal syndrome , 2009, Current heart failure reports.

[23]  M. Gheorghiade,et al.  Role of guanylate cyclase modulators in decompensated heart failure , 2009, Heart Failure Reviews.

[24]  Piotr Ponikowski,et al.  Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study , 2009, The Lancet.

[25]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[26]  M. Simoons,et al.  Low‐dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure , 2009, European journal of heart failure.

[27]  M. Jessup,et al.  The cardiorenal syndrome: do we need a change of strategy or a change of tactics? , 2009, Journal of the American College of Cardiology.

[28]  Gary S Francis,et al.  Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. , 2009, Journal of the American College of Cardiology.

[29]  V. Hasselblad,et al.  Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). , 2009, American heart journal.

[30]  P. Ponikowski,et al.  Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). , 2009, American heart journal.

[31]  P. Poole‐Wilson.  Publication Committee for the VMAC Investigators Randomized Controlled Trial Decompensated Congestive Heart Failure: A Intravenous Nesiritide vs Nitroglycerin for Treatment of , 2009 .

[32]  M. Givertz,et al.  Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. , 2009, Expert opinion on pharmacotherapy.

[33]  G. Felker,et al.  Relaxin, a pleiotropic vasodilator for the treatment of heart failure , 2008, Heart Failure Reviews.

[34]  G. Felker,et al.  Vasodilators in the treatment of acute heart failure: what we know, what we don’t , 2008, Heart Failure Reviews.

[35]  S. Gottlieb.  Adenosine A1 antagonists and the cardiorenal syndrome , 2008, Current heart failure reports.

[36]  C. O'connor,et al.  The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. , 2008, Journal of cardiac failure.

[37]  G. Filippatos,et al.  Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy? , 2008, Journal of cardiac failure.

[38]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[39]  R. Starling,et al.  Sodium nitroprusside for advanced low-output heart failure. , 2008, Journal of the American College of Cardiology.

[40]  D. Logeart,et al.  Transient worsening of renal function during hospitalization for acute heart failure alters outcome. , 2008, International journal of cardiology.

[41]  R. Califf,et al.  Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) , 2008, Circulation. Heart failure.

[42]  R. Schrier.  Blood urea nitrogen and serum creatinine: not married in heart failure. , 2008, Circulation. Heart failure.

[43]  V. Hasselblad,et al.  Cardiorenal interactions: insights from the ESCAPE trial. , 2008, Journal of the American College of Cardiology.

[44]  T. Nakata,et al.  Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy). , 2008, American heart journal.

[45]  M. Gheorghiade,et al.  Fluid overload in acute heart failure — Re‐distribution and other mechanisms beyond fluid accumulation , 2008, European journal of heart failure.

[46]  V. Vallon,et al.  Adenosine and kidney function: Potential implications in patients with heart failure , 2008, European journal of heart failure.

[47]  M. Metra,et al.  Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance , 2008, European journal of heart failure.

[48]  U. Elkayam,et al.  Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action , 2008, Circulation.

[49]  M. Metra,et al.  The pathophysiology of acute heart failure--it is a lot about fluid accumulation. , 2008, American heart journal.

[50]  Christopher M O'Connor,et al.  The pathophysiology of acute heart failure--is it all about fluid accumulation? , 2008, American heart journal.

[51]  H. C. Ho,et al.  Circulating blood volume measurements correlate poorly with pulmonary artery catheter measurements. , 2008, Hawaii medical journal.

[52]  A. Erdem,et al.  Levosimendan Improves Renal Function in Patients with Acute Decompensated Heart Failure: Comparison with Dobutamine , 2007, Cardiovascular Drugs and Therapy.

[53]  B. Massie,et al.  The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. , 2007, Journal of the American College of Cardiology.

[54]  John G F Cleland,et al.  Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. , 2007, Journal of cardiac failure.

[55]  H. Dittrich,et al.  The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. , 2007, Journal of cardiac failure.

[56]  D. J. Veldhuisen,et al.  Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction , 2007, European journal of heart failure.

[57]  G. Fonarow,et al.  High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. , 2007, Journal of cardiac failure.

[58]  M. Bunc,et al.  Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. , 2007, Journal of cardiac failure.

[59]  Gerasimos Filippatos,et al.  Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. , 2007, Journal of cardiac failure.

[60]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[61]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[62]  M. Guglin,et al.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[63]  M. Nieminen,et al.  Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. , 2006, European heart journal.

[64]  T. Buclin,et al.  Effect of dronedarone on renal function in healthy subjects , 2005, British journal of clinical pharmacology.

[65]  V. Roger,et al.  Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. , 2006, Journal of cardiac failure.

[66]  M. Komajda,et al.  Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). , 2006, European heart journal.

[67]  J. H. Patterson,et al.  Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline , 2022 .

[68]  J. Ouyang,et al.  Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. , 2006, American journal of physiology. Renal physiology.

[69]  R. Garrick.  Metaanalysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or DeathFriedrich JO, Adhikari N, Herridge MS, et al (St Michaeľs Hosp, Toronto; Sunnybrook and Women's College, Toronto; Toronto Gen Hosp; et al) Ann Intern Med 142:510–524, 2005§ , 2006 .

[70]  R. Bourge,et al.  Ultrafiltration: a new approach toward mechanical diuresis in heart failure. , 2005, Journal of the American College of Cardiology.

[71]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[72]  K. Aaronson,et al.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.

[73]  Joseph Beyene,et al.  Meta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death , 2005, Annals of Internal Medicine.

[74]  K. Aaronson,et al.  Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.

[75]  J. Kindler,et al.  Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure , 1979, Klinische Wochenschrift.

[76]  A. Burger,et al.  Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. , 2004, The American journal of cardiology.

[77]  P. Armstrong,et al.  Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.

[78]  C. O'connor,et al.  Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. , 2004, American heart journal.

[79]  C. O'connor,et al.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. , 2004, Journal of the American College of Cardiology.

[80]  James Fang,et al.  Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. , 2003, Journal of the American College of Cardiology.

[81]  D. Fliser,et al.  Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure , 2003, European journal of clinical investigation.

[82]  H. Krumholz,et al.  Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? , 2002, Journal of cardiac failure.

[83]  C. O'connor,et al.  The prognostic importance of different definitions of worsening renal function in congestive heart failure. , 2002, Journal of cardiac failure.

[84]  C. Price,et al.  Cystatin C: an improved estimator of glomerular filtration rate? , 2002, Clinical chemistry.

[85]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[86]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[87]  S. Gottlieb,et al.  BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.

[88]  H Ector,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[89]  A. Levey,et al.  Prediction equations to estimate glomerular filtration rate: an update , 2001, Current opinion in nephrology and hypertension.

[90]  J. Kellum,et al.  Use of dopamine in acute renal failure: A meta-analysis , 2001, Critical care medicine.

[91]  C. Blocher,et al.  Effects of increased renal parenchymal pressure on renal function. , 2000, The Journal of trauma.

[92]  H. Krumholz,et al.  Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. , 2000, The American journal of cardiology.

[93]  F. Zannad,et al.  Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. , 2000, American heart journal.

[94]  M. Fisher,et al.  Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[95]  J. Avorn,et al.  Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) , 1999, American heart journal.

[96]  M. Koopman,et al.  A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? , 1999, Journal of internal medicine.

[97]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[98]  M. Hori,et al.  Plasma adenosine levels increase in patients with chronic heart failure. , 1997, Circulation.

[99]  U. Elkayam,et al.  Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. , 1996, Journal of the American College of Cardiology.

[100]  G. Bakris,et al.  Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. , 1993, The American journal of physiology.

[101]  K. Swedberg,et al.  Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). , 1992, The American journal of cardiology.

[102]  I. Reid.  Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. , 1992, The American journal of physiology.

[103]  A. Grubb,et al.  Diagnostic value of analysis of cystatin C and protein HC in biological fluids. , 1992, Clinical nephrology.

[104]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[105]  J. Laragh,et al.  A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. , 1988, American journal of hypertension.

[106]  T. LeJemtel,et al.  Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure. , 1985, Circulation.

[107]  B. J. Tucker,et al.  Effect of furosemide administration on glomerular and tubular dynamics in the rat. , 1984, Kidney international.

[108]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[109]  C. Leier,et al.  Comparative Systemic and Regional Hemodynamic Effects of Dopamine and Dobutamine in Patients with Cardiomyopathic Heart Failure , 1978, Circulation.

[110]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[111]  M. Maxwell,et al.  RENAL VENOUS PRESSURE IN CHRONIC CONGESTIVE HEART FAILURE. , 1950, The Journal of clinical investigation.

[112]  F. R. Winton,et al.  The influence of venous pressure on the isolated mammalian kidney , 1931, The Journal of physiology.